Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer's disease-like mice overexpressing the human mutant amyloid precursor protein

Pharmacological Research

Volumn 130, Issue , 2018, Pages 366-373

  Maccarrone, Mauro ^a,b   Totaro, Antonio ^b   Leuti, Alessandro ^a,b   Giacovazzo, Giacomo ^b,c   Scipioni, Lucia ^a,b   Mango, Dalila ^d   Coccurello, Roberto ^b,c   Nisticò, Robert ^d,e   Oddi, Sergio ^b,f  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CNR   (Italy)

^d EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF TERAMO   (Italy)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Cannabinoid receptor; Hippocampus; Transgenic mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CANNABINOID 1 RECEPTOR; CAVEOLIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; MUTANT PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MALE; MICE, TRANSGENIC; MUTATION; RECEPTOR, CANNABINOID, CB1;

EID: 85042222810     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.02.009     Document Type: Article

References (45)

1. Alzheimer's Disease International (AZ), World Alzheimer Report., 2015, Alzheimer's Dis Int., London, UK, 2015 https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. (Accessed 15 June 2017).
2. Ising, C., Stanley, M., Holtzman, D.M., Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clin. Pharmacol. Ther. 98 (2015), 469–471, 10.1002/cpt.200.
3. Selkoe, D.J., Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 81, 2001, s1 http://physrev.physiology.org/content/81/2/741.full-text.pdf+html. (Accessed 15 June 2017).
4. Hardy, J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356, 10.1126/science.1072994 (80-.).
5. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008), 837–842, 10.1038/nm1782.
6. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., Watanabe, M., Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89 (2009), 309–380, 10.1152/physrev.00019.2008.
7. Mechoulam, R., Parker, L.A., The endocannabinoid system and the brain. Annu. Rev. Psychol. 64 (2013), 21–47, 10.1146/annurev-psych-113011-143739.
8. Miller, L.K., Devi, L.A., The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 63 (2011), 461–470, 10.1124/pr.110.003491.
9. Bedse, G., Romano, A., Lavecchia, A.M., Cassano, T., Gaetani, S., The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 43 (2015), 1115–1136.
10. Mulder, J., Zilberter, M., Pasquaré, S.J., Alpár, A., Schulte, G., Ferreira, S.G., Köfalvi, A., Martín-Moreno, A.M., Keimpema, E., Tanila, H., Watanabe, M., MacKie, K., Hortobágyi, T., De Ceballos, M.L., Harkany, T., Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134 (2011), 1041–1060, 10.1093/brain/awr046.
11. Sperling, R.A., Karlawish, J., Johnson, K.A., Preclinical Alzheimer disease–the challenges ahead. Nat Rev Neurol., 2013, 54, 10.1038/nrneurol.2012.241.
12. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice. Science 274 (1996), 99–102 (Published by: American Association for the Advancement of Science Stable URL: http://www.jstor.org/stable/2891864).
13. Kawarabayashi, T., Younkin, L., Saido, T., Shoji, M., Ashe, K., Younkin, S., Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001), 372–381 http://www.jneurosci.org/content/21/2/372.short.
14. Persaud-Sawin, D.A., Lightcap, S., Harry, G.J., Isolation of rafts from mouse brain tissue by a detergent-free method. J. Lipid Res. 50 (2009), 759–767, 10.1194/jlr.D800037-JLR200.
15. Oddi, S., Stepniewski, T.M., Totaro, A., Selent, J., Scipioni, L., Dufrusine, B., Fezza, F., Dainese, E., Maccarrone, M., Palmitoylation of cysteine 415 of CB1 receptor affects ligand-stimulated internalization and selective interaction with membrane cholesterol and caveolin 1. Biochim. Biophys. Acta-Mol. Cell Biol. Lipids 2017 (1862), 523–532, 10.1016/j.bbalip.2017.02.004.
16. Nisticò, R., Mango, D., Mandolesi, G., Piccinin, S., Berretta, N., Pignatelli, M., Feligioni, M., Musella, A., Gentile, A., Mori, F., Bernardi, G., Nicoletti, F., Mercuri, N.B., Centonze, D., Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One, 8, 2013, e54666, 10.1371/journal.pone.0054666.
17. i2 protein. Biotechnol. Appl. Biochem., 2017, 10.1002/bab.157.
18. Mukhopadhyay, S., McIntosh, H.H., Houston, D.B., Howlett, A.C., The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol. 57 (2000), 162–170 http://www.ncbi.nlm.nih.gov/pubmed/10617691.
19. Bari, M., Oddi, S., De Simone, C., Spagnolo, P., Gasperi, V., Battista, N., Centonze, D., Maccarrone, M., Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology, 54, 2008, 10.1016/j.neuropharm.2007.06.030.
20. Keren, O., Sarne, Y., Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res. 980 (2003), 197–205 http://www.ncbi.nlm.nih.gov/pubmed/12867259. (Accessed 3 August 2017).
21. Wu, D.-F., Yang, L.-Q., Goschke, A., Stumm, R., Brandenburg, L.-O., Liang, Y.-J., Höllt, V., Koch, T., Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J. Neurochem. 104 (2008), 1132–1143, 10.1111/j.1471-4159.2007.05063.x.
22. Hoffman, A.F., Lupica, C.R., Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 20 (2000), 2470–2479 http://www.ncbi.nlm.nih.gov/pubmed/10729327. (Accessed 11 September 2017).
23. Campbell, V.A., Gowran, A., Alzheimer's disease; taking the edge off with cannabinoids?. Br. J. Pharmacol. 152 (2007), 655–662 http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0707446/pdf. (Accessed 4 December 2015).
24. Chen, G., Chen, K.S., Knox, J., Inglis, J., Bernard, A., Martin, S.J., Justice, A., McConlogue, L., Games, D., Freedman, S.B., Morris, R.G., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 (2000), 975–979, 10.1038/35050103.
25. Cachope, R., Functional diversity on synaptic plasticity mediated by endocannabinoids. Philos. Trans. Royal Soc. Lond. B. Biol. Sci. 367 (2012), 3242–3253, 10.1098/rstb.2011.0386.
26. Kalifa, S., Polston, E.K., Allard, J.S., Manaye, K.F., Distribution patterns of cannabinoid C receptors in the hippocampus of APP swe/PS1 ΔE9 double transgenic mice. Brain Res., 2011, B1, 10.1016/j.brainres.2010.12.061.
27. Aso, E., Palomer, E., Juvés, S., Maldonado, R., Muñoz, F.J., Ferrer, I., CB 1 agonist ACEA protects neurons and reduces the cognitive impairment of A[Formula presented]PP/PS1 mice. J. Alzheimer's Dis. 30 (2012), 439–459, 10.3233/JAD-2012-111862.
28. Bedse, G., Romano, A., Cianci, S., Lavecchia, A.M., Lorenzo, P., Elphick, M.R., Laferla, F.M., Vendemiale, G., Grillo, C., Altieri, F., Cassano, T., Gaetani, S., Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. J. Alzheimer's Dis. JAD. 40 (2014), 701–712, 10.3233/JAD-131910.
29. Lafourcade, M., Larrieu, T., Mato, S., Duffaud, A., Sepers, M., Matias, I., De Smedt-Peyrusse, V., Labrousse, V.F., Bretillon, L., Matute, C., Rodríguez-Puertas, R., Layé, S., Manzoni, O.J., Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat. Neurosci. 14 (2011), 345–350, 10.1038/nn.2736.
30. Maccarrone, M., De Chiara, V., Gasperi, V., Viscomi, M.T., Rossi, S., Oddi, S., Molinari, M., Musella, A., Finazzi-Agrò, A., Centonze, D., Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J. Neurochem., 109, 2009, 10.1111/j.1471-4159.2009.05948.
31. Rozenfeld, R., Devi, L.A., Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 22 (2008), 2311–2322, 10.1096/fj.07-102731.
32. Martini, L., Waldhoer, M., Pusch, M., Kharazia, V., Fong, J., Lee, J.H., Freissmuth, C., Whistler, J.L., Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J. 21 (2007), 802–811, 10.1096/fj.06-7132com.
33. Niehaus, J.L., Liu, Y., Wallis, K.T., Egertova, M., Bhartur, S.G., Mukhopadhyay, S., Shi, S., He, H., Selley, D.E., Howlett, A.C., Elphick, M.R., Lewis, D.L., CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. 72 (2007), 1557–1566, 10.1124/mol.107.039263.
34. Bari, M., Paradisi, A., Pasquariello, N., Maccarrone, M., Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J. Neurosci. Res. 81 (2005), 275–283, 10.1002/jnr.20546.
35. Asimaki, O., Leondaritis, G., Lois, G., Sakellaridis, N., Mangoura, D., Cannabinoid 1 receptor-dependent transactivation of fibroblast growth factor receptor 1 emanates from lipid rafts and amplifies extracellular signal-regulated kinase 1/2 activation in embryonic cortical neurons. J. Neurochem. 116 (2011), 866–873, 10.1111/j.1471-4159.2010.07030.x.
36. Nelson, C.D., Sheng, M., GPR3 stimulates Aβ production via interactions with APP and β-Arrestin2. PLoS One, 8, 2013, e74680, 10.1371/journal.pone.0074680.
37. Zhang, F., Gannon, M., Chen, Y., Zhou, L., Jiao, K., Wang, Q., The amyloid precursor protein modulates α2A-adrenergic receptor endocytosis and signaling through disrupting arrestin 3 recruitment. FASEB J. 10 (2017), 4434–4446, 10.1096/fj.201700346R (fj. 201700346R).
38. Ikezu, T., Trapp, B.D., Song, K.S., Schlegel, A., Lisanti, M.P., Okamoto, T., Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid precursor protein. J. Biol. Chem. 273 (1998), 10485–10495, 10.1074/JBC.273.17.10485.
39. Couet, J., Li, S., Okamoto, T., Ikezu, T., Lisanti, M.P., Identification of peptide and protein ligands for the caveolin-scaffolding domain. Biochemistry 272 (1997), 6525–6533, 10.1074/jbc.272.10.6525.
40. Byrne, D.P., Dart, C., Rigden, D.J., Evaluating caveolin interactions: do proteins interact with the caveolin scaffolding domain through a widespread aromatic residue-rich motif?. PLoS One, 7, 2012, e44879, 10.1371/journal.pone.0044879.
41. Hájos, N., Katona, I., Naiem, S.S., MacKie, K., Ledent, C., Mody, I., Freund, T.F., Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci. 12 (2000), 3239–3249 http://www.ncbi.nlm.nih.gov/pubmed/10998107. (Accessed 19 September 2017).
42. Wise, L.E., Thorpe, A.J., Lichtman, A.H., Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. Neuropsychopharmacology 34 (2009), 2072–2080, 10.1038/npp.2009.31.
43. Bohme, G.A., Laville, M., Ledent, C., Parmentier, M., Imperato, A., Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 95 (2000), 5–7 http://www.ncbi.nlm.nih.gov/pubmed/10619457. (Accessed 19 September 2017).
44. Bilkei-Gorzo, A., Racz, I., Valverde, O., Otto, M., Michel, K., Sastre, M., Sarstre, M., Zimmer, A., Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 15670–15675, 10.1073/pnas.0504640102.
45. Haghani, M., Shabani, M., Javan, M., Motamedi, F., Janahmadi, M., CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell. Physiol. Biochem. 29 (2012), 391–406, 10.1159/000338494.